GLP-1 agonists like Novo Nordisk's Ozempic and Wegovy can lead to changing tastes, making high-fat and sweet foods less appealing.
Food giants are introducing new products with smaller portions and more protein, responding to the impact of GLP-1 drugs on appetite and nutrient intake.
Collection
[
|
...
]